Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 20/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 19/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 18/20 | 0.62 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24461611 | 0.94 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751356 | 0.92 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751347 | 0.91 | MAPKAPK5 (0.60) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751353 | 0.87 | MAPKAPK5 (0.57) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461734 | 0.87 | MAPKAPK5 (0.63) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751443 | 0.87 | MAPKAPK5 (0.64) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL23000656 | 0.86 | MAPKAPK5 (0.64) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL24461613 | 0.86 | MAPKAPK5 (0.62) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL29617119 | 0.86 | MAPKAPK5 (0.64) | MAPKAPK5MAPK14MAPK1MAPKAPK2 | |
| SCHEMBL25751357 | 0.86 | MAPKAPK5 (0.56) | MAPKAPK5MAPK14MAPK1MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | ACLARIS THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230286950-A1 | METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230202999-A9 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767309-B2 | Methods of synthesizing substituted pyridinone-pyridinyl compounds | PIR, PUM1, ZRANB2 | MAPKAPK5 848/4885MAPK14 2275/4885MAPK1 924/4885 |
| US-20230202999-A9 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PIR, PUM1, ZRANB2 | MAPKAPK5 848/4885MAPK14 2275/4885MAPK1 924/4885 |
| US-20230286950-A1 | METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | PDXK, DHPS, HCCS | MAPKAPK5 1249/4885MAPK14 714/4885MAPK1 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.